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Abstract 31 
Background: Protein glycation is a key mechanism involved in chronic diseases 32 
development in both diabetic and non-diabetic individuals. About 12-18% of circulating 33 
proteins are glycated in vivo in normoglycaemic blood, but in-vitro studies have hitherto 34 
failed to demonstrate glucose-driven glycation below concentration of 30mM. 35 
 Methods: Bovine Serum Albumin (BSA), reduced BSA (mercaptalbumin), (both 40g/L) and 36 
human plasma were incubated with glucose concentrations 0-30 mM for 4 weeks at 37
o
C.  37 
All were tested pre-oxidized for 8 hours prior to glycation with 10nM H202, or continuously 38 
exposed to 10nM H2O2 throughout the incubation period. Fructosamine was measured 39 
(nitroblue tetrazolium method) at two and four weeks. 40 
Results: Oxidized BSA (both pre-oxidised and continuously exposed to H2O2) was more 41 
readily glycated than native BSA at all glucose concentrations (p=0.03). Moreover, only 42 
oxidized BSA was glycated at physiological glucose concentration (5 mM) compared to 43 
glucose-free control (glycation increased by 35% compared to native albumin p<0.05). Both 44 
5 and 10 mM glucose led to higher glycation when mercaptalbumin was oxidised than un-45 
oxidised (p<0.05). Fructosamine concentration in human plasma was also significantly higher 46 
when oxidized and exposed to 5 mM glucose, compared to non-oxidised plasma (p=0.03). 47 
The interaction between glucose concentration and oxidation was found to be significant in 48 
all protein models (p<0.05).   49 
Conclusion The current study has for the first time demonstrated albumin glycation in-vitro, 50 
using physiological concentrations of albumin, glucose and hydrogen peroxide, identifying 51 
low-grade oxidative stress as a key element early in the glycation process.  52 
 53 
Key-Words: oxidative stress, hydrogen peroxide, albumin, plasma, glucose, 54 
mercaptalbumin, glycation, glucose 55 
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Introduction 59 
 60 
Protein glycation is the non-enzymatic glycosylation reaction between reducing sugars and 61 
amine residues in proteins[1]. It is usually considered to be driven by elevated glucose 62 
concentrations. Products of this reaction include Advanced Glycation End-products (AGEs) 63 
which are stable and accumulate in the body where they may exert antigenic effects, and 64 
contribute to tissue damage such as atherogenesis[2-3]. One early-glycation product is 65 
glycated hemoglobin (HbA1c), used as a biomarker for the diagnosis of diabetes and 66 
monitoring of glucose control in diabetic individuals[4]. Monitoring, and minimizing, 67 
glycative damage in diabetic care is of high importance, as glycated proteins and AGEs are 68 
implicated in cataract, neuropathy, nephropathy as well as macrovascular diseases[5]. 69 
 70 
However, glycation also occurs in non-diabetic people, in whom up to 6 % of hemoglobin 71 
and 12-16% of serum albumin is glycated[6], without exposure to high glucose 72 
concentrations (fasting plasma glucose <6 mmol/L). Protein glycation heralds tissue damage 73 
and function loss, in the normal aging process and as part of the pathogenesis of various 74 
chronic diseases. Receptors for Advanced Glycation End-products (RAGE), found in most 75 
tissues, have potent immunomodulatory actions, promoting reactive oxygen species (ROS) 76 
production and inflammation. Elevated HbA1c can serve as a proxy for both pre-diabetes and 77 
metabolic syndrome, as shown in large longitudinal studies[7]. In both non-diabetic and 78 
diabetic subjects, HbA1c correlates with coronary heart disease (CHD) risk factors and 79 
predicts future CHD and strokes[8]. A recent study showed that among non-diabetic 80 
individuals who did not develop diabetes in the next 3.5 years, those with a higher yet 81 
physiological level of HbA1c had higher risk for CVD, in both men and women and after 82 
controlling for traditional risk factors[9]. 83 
 84 
The mechanisms leading to protein glycation in the non-diabetic state are not established. The 85 
very few in vitro studies which have used physiological concentrations are inconclusive as to 86 
whether glucose, alone, can successfully promote glycation[10-11]. In diabetic subjects, 87 
protein glycation is assumed to be mainly a mass action effect driven by high glucose 88 
concentration. However the full process of glycation in diabetes is in fact driven by two 89 
separate factors - the concentration of sugars in the initiation phase (mainly glucose, due to its 90 
high concentration in blood), and later the pro-oxidant status during Maillard reactions to 91 
generate stable AGEs[12]. We hypothesize that at physiological concentrations of glucose, 92 
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oxidation may have another role in initiating glycation, supporting earlier speculations from a 93 
cross-sectional study in non-diabetic individuals which showed inverse associations between 94 
protein glycation and dietary fruit and vegetable consumption, plasma vitamin C and plasma 95 
tocopherol[13]. Defining an early, preventable oxidative component to the overall glycation 96 
mechanism could be of importance in the management of pre-diabetes, when glucose 97 
metabolism is only mildly disrupted and glucose-centered clinical approaches might have 98 
little effect. 99 
 100 
The current study investigates the effect of introducing a mildly pro-oxidative state (hydrogen 101 
peroxide at a low physiological concentration of 10nM[14]) on the susceptibility of protein 102 
(albumin) to glycation, particularly at physiological and near-physiological glucose 103 
concentrations. Another common glycation driver, methylglyoxal, which causes glycative 104 
damage in a more oxidative fashion than glucose, was used in physiological concentration 105 
both alone and in combination with glucose, to explore possible synergistic effects.  106 
This oxidation-driven glycation hypothesis was also tested on reduced albumin 107 
(mercaptalbumin) on the assumption that commercially source native albumin would be 108 
already partly oxidized. This work was also extended to proteins in human plasma to extend 109 
the physiological relevance of our findings. 110 
 111 
 112 
Material and methods 113 
Impact of constant oxidation & pre-oxidation on BSA glycation 114 
Chemicals 115 
Bovine serum albumin (BSA), sodium azide, nitroblue tetrazolium, d-glucose, methylglyoxal, 116 
PBS, 1-deoxy-1-morpholinofructose (DMF), hydrogen peroxide, sulphuric acid, dithiothreitol 117 
and quinine were purchased from Sigma-Aldrich (Dorset, UK). SnakeSkin Dialysis Tubing, 118 
3.5K MWCO was purchased from Thermo Fisher Scientific (Nottinghamshire, UK). 119 
 120 
Glycation of pre-oxidized BSA 121 
BSA (80g/L) was incubated with H2O2 (10nM) for 8 hours at 37
o
C in PBS and was then 122 
dialyzed against PBS (8:1) for another 8 hours. The dialysate was discarded and replaced 123 
with fresh PBS three times during dialysis. 124 
 125 
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To measure the effect of protein pre-oxidation on the susceptibility of BSA to glycation, both 126 
native and pre-oxidized albumin (40g/L) were incubated in the presence of glucose (0, 5, 10, 127 
20 and 30mM) for 4 weeks. The combination of methylglyoxal (150nM) and glucose (0, 10 128 
or 20mM) was also studied in order to replicate glycoxidative conditions of albumin in the 129 
circulation. All incubations were repeated in 6 replicates. 130 
 131 
Albumin glycoxidation  132 
All incubations took place in PBS with sodium azide (0.2g/L) and a final volume of 1.5ml. 133 
To investigate the effect of continuous exposure to oxidative damage in the progress of the 134 
glycation reaction (glycoxidation) native BSA was incubated with glucose (0,5, 10, 20, or 135 
30mM) and combinations of methylglyoxal (150nM) plus glucose (0,10,20mM) for 4 weeks 136 
in the presence of H2O2 (10nM). Native BSA was also incubated under the same conditions 137 
without H2O2 (10nM) to serve as a reference. All incubations were repeated in 6 replicates. 138 
 139 
Comparison of the effect of constant glycation among BSA, mercaptalbumin & human 140 
plasma 141 
To enhance a concern over the oxidation status of the bovine serum albumin sold by Sigma-142 
Aldrich, the BSA used in the experiments was i) pre-treated with 1.5mM dithiothreitol (DTT) 143 
at 37
o
C for  15min and then DTT was removed by extensive dialysis against PBS for 10 144 
hours to create mercapralbumin and ii) BSA as bought from Sigma-Aldrich. 145 
 146 
In order to investigate the effect of hydrogen peroxide exposure in plasma proteins glycation, 147 
pooled plasma from 8 healthy, normal weight volunteers was collected in heparin tubes after 148 
an overnight fast.  149 
 150 
Protein glycoxidation  151 
All incubations took place in PBS with sodium azide (0.2g/L) and a final volume of 1.5ml. 152 
To investigate the effect of constant exposure to oxidative damage in the progress of the 153 
glycation reaction (glycoxidation) native BSA and native mercaptalbumin was incubated with 154 
glucose (0, 5, 10 or 20mM) for 4 weeks in the presence of H2O2 (10nM). Proteins were also 155 
incubated under the same conditions without H2O2 (10nM) to serve as a reference. 156 
 157 
The glucose concentration of 30mM was not employed as it is a highly supra-physiological 158 
concentration and the combinations of methylglyoxal plus glucose were also not employed. 159 
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All incubations were repeated in 5 replicates. 160 
 161 
Fructosamine measurement 162 
The NBT assay was modified in this experiment using a larger amount of sample (25 vs 10 163 
µL) which resulted in a smaller Coefficient of Variation. 164 
Fructosamine levels were measured at week 2 and 4 with the NBT assay, performed in 165 
microplates as described previously [15].  Briefly, samples (25µL) were added to of sodium 166 
carbonate buffer (100µL, 100mM, and pH 10.8) with Nitroblue Tetrazolium (0.25mM). 167 
Microplates were incubated for 15 min at 37
o
C and measured spectrophometrically against 168 
controls at 550nm after 10 and 15 min of incubation. The difference between the two 169 
readings was used to calculate concentrations. The fructosamine analog 1-deoxy-1-170 
morpholinofructose (DMF) was used as a standard. All fructosamine measurements were 171 
performed in duplicate. Standards and NBT reagent were made fresh every week and stored 172 
at -20
o
C and 4
o
C respectively. All samples were stored at -20
o
C. 173 
 174 
Statistical analysis 175 
All combinations of oxidative damage and glycation drivers were tested as five or six true 176 
replicates, according to the experiment. The independent sample t-test was used to assess the 177 
differences in glycation between native BSA and either of the oxidation set-ups. Difference in 178 
fructosamine production between glucose levels and glycation drivers were tested using a 179 
one-way ANOVA and Tukey’s post-hoc test. Differences between exposure to oxidation and 180 
no oxidation were studied in each protein system separately using one-way ANOVA and the 181 
ineraction between glucose levels and oxidation was studied using two-way ANOVA. 182 
Statistical analysis was performed using PASW 18. 183 
 184 
 185 
Results 186 
 187 
Effect of constant oxidation on BSA glycation 188 
Incubation of native BSA (40g/L) with glucose concentrations below 20mM did not lead to 189 
measurable levels of glycated BSA measured after 2 weeks, with or without 150nM 190 
methylglyoxal, compared to glucose-free control (Table 1). After 4 weeks, incubation with 191 
10mM glucose (with or without methylglyoxal) significantly promoted glycation in native 192 
BSA compared to glucose-free control. Exposure to a physiological concentration of 193 
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hydrogen peroxide (10nM), however, led to significantly higher glycated BSA (measured as 194 
fructosamine) at the lower glucose concentrations of 10mM after 2 weeks, and 5 mM after 4 195 
weeks incubation (both p<0.05 vs. glucose free control). 196 
 197 
Using constantly-oxidized BSA generated significantly more fructosamine than native BSA 198 
after 2 weeks of incubation with 5, 10 and 20mM glucose (increased by 23%, 36% and 35% 199 
respectively). Similar results were observed with methylglyoxal (150 nM) alone (19% 200 
increase in fructosamine), and with a combination of methylglyoxal (150 nM) plus glucose at 201 
concentrations of 10 and 20mM, with 35% and 26% increases in fructosamine respectively 202 
(Figure 1). Significantly greater glycation of constantly-oxidized BSA compared to native 203 
BSA was also observed after 4 weeks at all glucose concentrations, and with combinations of 204 
glucose (10 & 20mM) and methylglyoxal (150nM) (Figure 2). In particular, incubation of 205 
BSA with 5mM glucose and 10mM H2O2 led to a 35% higher fructosamine concentration 206 
compared to the non-oxidised control (p=0.04). Although incubating BSA in presence of 207 
methylglyoxal (150nM) alone did not lead to significantly increased glycation after neither  2 208 
nor 4 weeks (Table 1), combining methylglyoxal (150nM) and glucose (10mM) had a 209 
synergistic effect on glycation of constantly-oxidised BSA after 4 weeks (p=0.02 vs. glucose 210 
alone), as well as some suggestion of an effect on native BSA (p=0.08) (data not shown). 211 
 212 
The individual impacts of glucose concentration and oxidation, as well as their interaction, on 213 
glycation over periods of 2 and 4 weeks were investigated using a two-way ANOVA. 214 
Oxidation had a significant effect on glycation at both two and four weeks (p<0.001) There 215 
was strong evidence for an interaction between continuous-oxidation and glucose 216 
concentration in driving glycation after 2 weeks of incubation (p<0.001) with a non-217 
significant indication of an effect of this interaction on glycation after 4 weeks (p=0.058). 218 
While removing data relating to methylglyoxal and glucose incubations from the analysis did 219 
not change impact on the significance of the effect of oxidation on protein glycation (p 220 
<0.001 at both two and four weeks), the interaction between oxidation and glucose 221 
concentration significantly affected glycation after both two and four weeks (p=0.001 and 222 
p=0.01, respectively).  223 
 224 
Effect of pre-oxidation on BSA glycation 225 
Incubation of native and pre-oxidised BSA with glucose concentrations lower than 20mM for 226 
two weeks did not lead to significantly more fructosamine being produced than the glucose-227 
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free control. Nonetheless the pre-oxidation step led to significantly higher glycation, 228 
compared to native BSA, after two weeks at the lowest glucose concentration (5mM) 229 
(p=0.016). 230 
 231 
A 4-week incubation with 5mM glucose alone was sufficient to drive glycation of pre-232 
oxidized BSA (p=0.03 vs. glucose-free control), but not native (un-oxidized) BSA which 233 
required at least 10mM glucose (p=0.001, Table 1).  234 
 235 
Comparison of the effect of constant-oxidation on BSA and mercaptalbumin glycation 236 
Reduction of BSA to mercaptalbumin was employed in order to investigate whether 237 
commercially available BSA, possibly being oxidised to some extent, would be more or less 238 
prone to subtle oxidation driven glycation. For this reason, DTT-treated BSA was incubated 239 
with glucose (0-20mM) in presence or absence of 10nM H2O2.  240 
 241 
When mercaptalbumin was incubated with 5 and 10mM glucose under constant oxidation for 242 
two weeks, significantly higher fructosamine levels were observed compared to non-oxidised  243 
mercaptalbumin (p=0.03 & p=0.006; respectively). While incubation for two weeks with 244 
5mM glucose was sufficient to drive higher glycation in constantly-oxidized mercaptalbumin 245 
than glucose-free control (p<0.001), non-oxidised mercaptalbumin required incubation with 246 
10mM glucose to lead to higher glycation than the glucose-free control (p<0.001). No 247 
differences between oxidized and non-oxidised mercaptalbumin were observed at week 4 248 
(Figure 3). 249 
 250 
Two-way ANOVA, analysing the effect of oxidation at all glucose levels, showed that 251 
oxidized mercaptalbumin was subject to higher glycation than non-oxidised, at both weeks 252 
two and four (p=0.003 & p=0.035 respectively). The interaction between glucose and 253 
oxidation was not significantly affecting glycation in both weeks (p for interaction glucose × 254 
oxidation = 0.48 & 0.78 for week 2 and 4 respectively). 255 
 256 
When mercaptalbumin glycation was compared to BSA glycation. Mercaptalbumin was more 257 
prone to glycation than BSA in both the presence and absence of H2O2. In the absence of 258 
H2O2 mercaptalbumin had higher fructosamine concentration than BSA at 5 and 10mM 259 
glucose at two weeks (p=0.004 & p=0.002 respectively) and that was significant at week 4 260 
for 5mM glucose (p=0.005) and nearly significant for 10mM glucose (p=0.06). In the 261 
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presence of H2O2 mercaptalbumin was again more successfully glycated than BSA at 5&10 262 
mM glucose at week 2 (p<0.001, for both) and nearly significantly more at 20mM (p=0.057). 263 
At week 4 mercaptalbumin was significantly more glycated than BSA only at 5mM glucose 264 
(p=0.04) (data not shown). 265 
 266 
Employing two-way ANOVA showed that mercaptalbumin was more prone to glycation than 267 
BSA (p<0.001) and there was a significant positive interaction between oxidation and the 268 
type of protein employed, in favour of mercaptalbumin (p interaction protein-type x 269 
oxidation= 0.047) at week 2. Although the interaction between the protein type and oxidation 270 
was not documented at week 4 (p=0.33), glycation was still positively affected by using 271 
mercaptalbumin rather than BSA (p<0.001) (data not shown). 272 
 273 
Effect of constant-oxidation on human plasma glycation 274 
Protein glycation in human plasma was studied to explore the reactions studied previously in 275 
a more complex protein system with antioxidant mechanisms in place and closer to human 276 
physiology.  Plasma exposure to constant hydrogen peroxide (10nM) promoted glycation 277 
when incubated with 5mM glucose for 2 weeks, compared to non-oxidised plasma (p=0.03). 278 
Surprisingly, this effect of oxidation was no present after 4 weeks, and actually led to 279 
significant lower fructosamine concentration for incubations with 10mM glucose compared 280 
to non-oxidised plasma (p=0.001) (Figure 5).  281 
 282 
Two-way ANOVA suggested that oxidation had no impact on glycation in human plasma at 283 
week two but it had a significant negative impact at week four (p=0.01). The interaction 284 
glucose × oxidation was also significant (p<0.001) at week four, only.  285 
 286 
 287 
Discussion 288 
 289 
Protein glycation was first described as part of the Maillard reactions cascade, as a cause of 290 
food-spoiling. Although the same reactions have been identified in-vivo, and glycated 291 
proteins are probably causally associated with the tissue damage that occurs during aging, in 292 
diabetes and other chronic diseases[5], there are still gaps in the understanding of the exact 293 
mechanisms involved.  It is striking that 12-18% of circulating albumin, and up to 6% of 294 
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haemoglobin is glycated in apparently healthy non-diabetic people, amongst whom most 295 
heart disease occurs[6]. 296 
 297 
Perhaps surprisingly, this study is the first to demonstrate in vitro protein glycation at 298 
physiological glucose concentrations. The clear effect of including an oxidative agent 299 
(hydrogen peroxide at a low, physiologically relevant concentration [14]), supports the 300 
concept of oxidative stress as a key mechanism behind in-vivo glycation of albumin in 301 
normoglycaemic individuals. It is worth stressing that the concentration of hydrogen peroxide 302 
used was very low. Although the literature is still controversial over the exact concentration 303 
of hydrogen peroxide in plasma with values up to 35 μM being documented[16], even the 304 
supporters of the theory that hydrogen peroxide concentration is not important in plasma 305 
documented values of 250nM[17],which 25 times higher than the concentration equipped in 306 
the current study. Several factors might explain why previous studies have failed to achieve 307 
glycation in vitro under physiological conditions.  We used a physiological concentration of 308 
albumin, while previous studies have used lower (sub-physiological) concentrations (0.01-7 309 
g/L)[18-19], and/or high (supra-physiological) glucose concentrations (30mM-0.5M)[20-21]. 310 
Albumin glycation had previously been achieved in the presence of 15mM glucose alone at 5 311 
weeks or 30mM glucose alone at 4 weeks [22]. With physiological glucose concentrations, 312 
results have varied according to sample treatment and methods used to measure glycation. 313 
Bourdon et al. [10] reported that incubation of albumin for 4 weeks with 5mM glucose did 314 
not promote glycation, while later reporting contradictory findings (with, however, glycation 315 
only implied from qualitative results[11]).   316 
 317 
Similarly, while methylglyoxal is a potent glycative molecule in supra-physiological 318 
conditions[19], it did not show significant glycative activity in physiological concentrations.  319 
Our data suggest it might act synergistically with glucose to promote glycation at lower 320 
glucose concentrations (10mM), but we demonstrated that both glucose and methylglyoxal at 321 
physiological concentrations will glycate albumin if it is oxidised. 322 
 323 
In both the BSA and mercaptalbumin models, glycation of the protein was significantly 324 
higher than the glucose-free control when exposed to a physiological concentration of 325 
hydrogen peroxide for two weeks. Although the effect of pre-oxidation and continuous 326 
oxidation were very similar with a favour towards continuous oxidation, in so low hydrogen 327 
peroxide concentrations the continuous oxidation model is more likely to be of physiological 328 
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relevance Continuous exposure to hydrogen peroxide led to higher fructosamine 329 
concentrations at all glucose levels and oxidation was also shown to act synergistically with 330 
glucose, as the interaction between the two was found to be significant in our experiments.  331 
Hydrogen peroxide positively interacts with glucose in promoting glycation reactions. One 332 
has to keep in mind that the hydrogen peroxide exposure was weak in term of concentration 333 
in order to resemble physiological condition and hence it is likely to induce important but 334 
subtle effects. When human plasma was exposed to hydrogen peroxide, glycation was 335 
significantly higher with 5mM glucose after two weeks, compared to the non-oxidized 336 
control. The opposite was found when oxidised plasma was incubated with 10mM glucose 337 
for 4 weeks, but the lower fructosamine concentration of the oxidised plasma in that case 338 
could be attributed both to increased protein instability and/or glycation being driven to the 339 
production of AGEs (not detectable by the NBT method used) rather than early-glycation 340 
products as fructosamine. 341 
 342 
Constant oxidative stress is clearly damaging and relevant to diabetic and obese chronic pro-343 
oxidant states, however a dynamic balance between pro- and anti-oxidant factors is usually 344 
present in plasma and other body fluids.  The level of oxidative stress fluctuates during the 345 
day (e.g. higher post-prandially) and a variety of events can trigger short-term production of 346 
Reactive Oxygen Species. Our results suggest that episodes of relatively unopposed 347 
oxidation, e.g. from infection or inflammation, or smoking, could damage proteins to 348 
promote subsequent glycation, as we have demonstrated with the increased susceptibility of 349 
pre-oxidized albumin to glycation at a physiological glucose concentration. This mechanism 350 
could apply in vivo.   351 
 352 
Recognizing that, in physiological systems, protein glycation depends on oxidative damage 353 
as well as glucose concentration has implications for scientific understanding and potentially 354 
for clinical practice. The term ‘glycoxidation’, currently restricted to the latter stages of 355 
Maillard reactions, seems more appropriate than simply ‘glycation’ to describe the overall in 356 
vivo protein glycation process, and similar protocols to ours would be appropriate to study the 357 
phenomenon in vitro. The quest for normoglycaemia in diabetes management is important to 358 
delay vascular and other complications, but potentially hazardous interventions are entirely 359 
directed at glucose-lowering: using insulin or anti-diabetic drugs intensively to reduce 360 
glycation has been associated with increased risk of hypoglycemia, and of mortality [23]. If 361 
oxidative stress is also involved as a trigger for protein glycation and tissue damage, then 362 
12 
 
approaches aimed solely at glucose handling are insufficient, and reducing oxidative stress 363 
might be less hazardous.  This is not arguing for indiscriminate or high-dose antioxidant 364 
treatments.  Several trials have suggested worse outcomes from antioxidant vitamin 365 
supplementation[24], leading to understandable prejudice against their effectiveness and 366 
safety, but a recent meta-analysis of 66 randomised controlled trials indicates benefit from 367 
vitamin E supplementation for primary prevention (where there is some baseline 368 
insufficiency)[25], and vitamin E also contributes to secondary prevention[26], renewing 369 
interest in antioxidant interventions. Our results support findings from the cross-sectional 370 
study of Bates et al.[13], which led to the hypothesis that dietary antioxidants may reduce 371 
tissue glycation. Also evidence from in-vitro studies suggest that antioxidants are having a 372 
protective role in protein glycation[20, 27]. Exposure to oxygen radicals such as TBH and 373 
H2O2 significantly increased haemoglobin glycation in-vitro and pre-treatment with vitamin E 374 
blocked that effect[28]. Replenishment of the antioxidant defences of GSH-deficient red 375 
blood cells, on the other hand, protected them against increased haemoglobin glycation[29], 376 
both supporting the hypothesis of oxidative stress being involved in protein glycation. 377 
 378 
The present studies suggest some important avenues for future research, as well as changes to 379 
commonly-used experimental models.  It is important to question accepted patho-380 
physiological mechanisms if they cannot be demonstrated in vivo at physiological 381 
concentrations.  Our evidence that mild oxidation plays an early role in AGE production is 382 
novel and explains a gap in the literature.  Prior reduction of BSA might indeed increase the 383 
oxidation potential of the protein and hence strengthen the effect of oxidation on glycation, as 384 
shown by the two-way ANOVA analysis. While being designed to replicate physiological 385 
conditions and employing a large number of replicates (6 instead of the usual 3) to reduce 386 
random errors under physiological conditions, the current study does have limitations. 387 
Albumin, although the major circulating protein, may not be representative of other 388 
glycation-prone proteins, and the results cannot provide an exact mechanism linking 389 
oxidative damage to glycation. Using human plasma led to slightly different results than BSA 390 
and mercaptalbumin. No effect on glycation was seen from oxidation at glucose levels above 391 
10mM after two weeks of incubation; that could be attributed to the fact that plasma from 392 
healthy volunteers involves different proteins with different degrees of pro-oxidation and 393 
glycation and also a much more competent antioxidant system which would be expected to 394 
rapidly scavenge ROS. Glycated proteins already present in plasma could also affect the 395 
speed and general kinetics of the reaction. Possible mechanisms involve protein damage by 396 
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hydrogen peroxide and/or increased glucose autoxidation in the presence of hydrogen 397 
peroxide, both likely to increase the affinity of the molecules for the non-enzymatic sugar 398 
linkage. There may be selective oxidation of amino acids: for example, tryptophan, a main 399 
site for protein glycation, is an oxidation site for human albumin [30-31], suggesting that 400 
oxidized amino acids maybe more susceptible to further glycative damage.  401 
 402 
 403 
404 
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Conclusion 405 
Oxidative damage, although known to be important for the late stages of protein glycation, 406 
has not previously been linked with the early stage of the Maillard reaction. Our data suggest 407 
that oxidative damage, induced by a very low (physiological) concentration of hydrogen 408 
peroxide, plays a critical early role in fructosamine production.  Importantly, the effect is 409 
seen at physiological glucose concentrations, potentially opening an avenue for new 410 
preventive treatments. Our experiments highlight the importance of oxidative stress on 411 
protein glycation, as a promoter and even a necessary condition to achieve glycation in 412 
physiological glucose concentrations.  413 
 414 
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Figure 1. Fructosamine concentration (mM DMF equivalent) after two weeks incubation with glucose and 420 
constant exposure to oxidation from hydrogen peroxide (10 nM). Two-way ANOVA analysis showed a 421 
significant effect of oxidation to promote glycation. 422 
 423 
  424 
*p<0.05 native vs. constant oxidation for each given glucose concentration 425 
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Figure 2. Fructosamine concentration (mM DMF equivalent) after four weeks incubation with glucose and 428 
constant exposure to oxidation from hydrogen peroxide (10 nM). Two-way ANOVA analysis showed a 429 
significant effect of oxidation to promote glycation. 430 
 431 
 *p<0.05 native vs. constant oxidation for each given glucose concentration 432 
 433 
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Table 1.Fructosamine concentration after two weeks incubation of albumin with different glucose 436 
concentrations, between and within treatments (glucose / MGO exposure and oxidation) 437 
 438 
 Week 2  
Glucose levels 
(mM) 
Oxidation status 
 Native 
Mean (SD) 
H2O2 10nM 
Mean(SD) 
p-value  
Native 
Mean (SD) 
Pre-Oxidized 
Mean(SD) 
p-value 
0 0.26(0.04) 0.27(0.02) 0.669  0.26(0.01) 0.26(0.03) 0.807 
5 0.31(0.04) 0.38(0.02) 0.017  0.23(0.02) 0.29(0.05) 0.016 
10 0.35(0.02) 0.53(0.02)* 0.001  0.26(0.04) 0.28(0.03) 0.177 
20 0.51(0.05)* 0.69(0.07)* 0.002  0.57(0.06)* 0.57(0.04)* 0.940 
30 0.82(0.06)* 0.82(0.03)* 0.987  0.79(0.10)* 0.64(0.10)* 0.041 
0+MGO 0.26(0.02) 0.31(0.01) 0.015  0.19(0.02) 0.19(0.03) 0.510 
10+MGO 0.34(0.05) 0.46(0.03)* 0.001  0.62(0.07)* 0.48(0.05)* 0.002 
20+MGO 0.53(0.08)* 0.67(0.01)* 0.008  0.46(0.05)* 0.39(0.07)* 0.048 
Oxidised vs native#  0.43(0.19) 0.51(0.20) <0.001  0.42(0.21) 0.40(0.16) 0.005 
 Week 4  
0 0.37(0.03) 0.39(0.09) 0.767  0.20(0.02) 0.17(0.02) 0.021 
5 0.40(0.09) 0.54(0.06)* 0.015  0.26(0.02) 0.24(0.02)* 0.063 
10 0.55(0.04)* 0.68(0.06)* 0.003  0.31(0.02)* 0.31(0.02)* 0.825 
20 0.78(0.04)* 0.92(0.04)* <0.001  0.56(0.05)* 0.52(0.07)* 0.292 
30 0.95(0.08)* 1.17(0.10)* 0.002  0.62(0.05)* 0.64(0.03)* 0.844 
0+MGO 0.43(0.02) 0.40(0.04) 0.590  0.22(0.02) 0.17(0.01) 0.016 
10+MGO 0.70(0.03)* 0.84(0.09)* 0.010  0.52(0.01)* 0.46(0.03)* 0.028 
20+MGO 0.86(0.07)* 1.05(0.12)* 0.015   0.40(0.02)* 0.33(0.01)* <0.001 
Oxidised vs native# 0.64(0.22) 0.75(0.29) <0.001  0.38(0.16) 0.36(0.17) <0.001 
*p<0.05 vs. glucose 0mM, 
# 
two-way ANOVA analysis 439 
 440 
 441 
  442 
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 443 
Figure 3. Fructosamine concentration (mM DMF equivalent) after two and four weeks incubation with 444 
glucose and constant exposure to oxidation from hydrogen peroxide (10 nM) in mercaptalbumin. Two-445 
way ANOVA analysis showed a significant effect of oxidation to promote glycation. 446 
 447 
 448 
Mercaptalbumin 449 
Week 2 450 
 451 
Week 4 452 
 453 
*p<0.05 native vs. constant oxidation  454 
  455 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
0 5 10 20 
Fr
u
ct
o
sa
m
in
e
 m
M
 (
D
M
F 
e
q
u
iv
al
e
n
t)
 
Glucose levels (mM) 
Without H2O2 
With H2O2 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
0 5 10 20 
Fr
u
ct
o
sa
m
in
e
 m
M
 (
D
M
F 
e
q
u
iv
al
e
n
t)
 
Glucose levels (mM) 
Without H2O2 
With H2O2 
* 
19 
 
Figure 4. Fructosamine concentration (mM DMF equivalent) after two and four weeks incubation with 456 
glucose and constant exposure to oxidation from hydrogen peroxide (10 nM) in human plasma. Two-457 
way ANOVA analysis showed a significant effect of oxidation to promote glycation. 458 
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*p<0.05 native vs. constant oxidation  466 
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